Orthopedic surgery or orthopedics (also spelled orthopaedics) is the branch of surgery concerned with conditions involving the musculoskeletal system. Orthopedic surgeons use both surgical and non-surgical means to treat musculoskeletal trauma, sports injuries, degenerative diseases, infections, tumors, and congenital conditions.
After a person receives acute care in a "regular" hospital for catastrophic illness, traumatic injury or a debilitating chronic condition, the next step in the process of recovery often involves a stay at an inpatient rehabilitation, or rehab, facility.Patients often have little warning when they're quickly moved to a rehab facility from acute care. Those who envision a long, leisurely recovery in a hospital or at home may find that the abrupt transition-and new responsibilities in rehab-leaves their heads spinning.
HealthSouth Corporation today announced plans to begin construction of a new 40-bed inpatient rehabilitation hospital in the Cypress area of northwest Houston in the fourth quarter. In connection with such plans, HealthSouth has signed a contract to purchase a 6-acre tract of land from an affiliate of Caldwell Companies, based in Houston. The land is located on the northeast corner of Highway 290 and FM 1960 in Houston.
Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.
The U.S. Food and Drug Administration (FDA) Orthopaedic and Rehabilitation Devices Panel today voted 9 for and 4 against (1 abstention) on safety and 10 for and 3 against (1 abstention) on effectiveness, that data including results from a large, prospective randomized clinical trial demonstrated the safety and effectiveness of AMPLIFY™ rhBMP-2 Matrix for fusions of the lower spine in patients with degenerative disc disease.
A total joint replacement registry based on carefully designed and integrated technology can enhance patient safety, quality of care, cost-effectiveness and research, according to a paper published in the online and print editions of Clinical Orthopedics and Related Research, a journal of the Association of Bone and Joint Surgeons.
BioTime, Inc. announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kits and media for the culture of each line.
Trinity Orthopedics LLC, a medical device company that develops and markets products for minimally invasive spine surgery, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a monoplanar pedicle screw method, system and kit. Trinity currently markets the posterior fixation system in the United States under the ReStor name.
Foundation Surgical Hospital has selected Healthcare Management Systems, Inc. to provide a full suite of integrated clinical and financial information system applications for the 64-bed orthopedic and neuro-spine facility, located in the Greater Houston market.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
Wendy R. Fleishman, a partner in the national plaintiffs' law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that William Kokoszka filed a personal injury lawsuit against Zimmer Inc., the nation's largest producer of orthopedic devices. Following his 2006 hip replacement, Kokoszka suffered constant and devastating pain for over 18 months before having to undergo a second hip replacement surgery due to an allegedly defective hip implant manufactured and sold by Zimmer under the brand name Durom Cup.
An emerging medical technology company focused on regenerative medicine, reports that the Company was granted European patent EP 1,452,141 entitled "Shock Wave Generating Device," which provides the Company exclusive rights in human and animal treatment devices that include the novel use of piezoelectric fibers to produce acoustic energy in the shock wave spectrum.
Factory Reimbursement announced a complete update of its popular catalog of country-specific medical device Reimbursement Reports. Additionally, the Reimbursement Reports are now available for two new markets: The Netherlands and Belgium. Formerly known as the Jacoti Reports, the ready-to-download reports offer the most comprehensive information available about today's medical device reimbursement regulations in seven European Union countries.
BioMimetic Therapeutics, Inc., announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share.
Taking a few small steps toward protecting your knees when you are younger might help you avoid debilitating problems when you get older.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Medical device company Vertos Medical Inc. has announced the unveiling of 12-week clinical data from its prospective, 75-patient MiDAS I (mild Decompression Alternative to open Surgery) study that further validate the safety and efficacy of mild for the treatment of lumbar spinal stenosis (LSS). Consistent with the positive six-week study results released in March and May, the new MiDAS I data demonstrate that mild patients continued to experience statistically significant improvement in pain, physical function and mobility 12 weeks following treatment.
Hip problems can sideline even the best athletes, but a new study led by orthopedic experts from Rush University Medical Center indicates that the use of minimally invasive arthroscopic surgery to treat painful disorders of the hip may give athletes who undergo the procedure another opportunity to resume their sport back at their pre-injury level of competition.
Kent L. Klaudt, a partner in the national plaintiffs' law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that James Cabral today filed a personal injury lawsuit against Zimmer Inc., the nation's largest producer of orthopedic devices. Cabral has suffered constant and devastating pain for over 18 months and will have to undergo a second hip replacement surgery due to an allegedly defective hip implant manufactured and sold by Zimmer under the brand name Durom Cup.
Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products, announced today its acquisition of substantially all of the assets of Cytosol Laboratories, Inc., located in Braintree, Massachusetts, a market leader in production of small volume anticoagulants.
Athletes who undergo arthroscopic surgery for a mechanical disorder of the hip have a good chance of being able to return to their sport at a high level of competition, according to a study that will be presented at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, R.I. Almost 80 percent of patients were able to return to play after hip arthroscopy at an average of 9.4 months after surgery, and roughly 90 percent were able to return to the same level of competition.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.